| Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing GM Frampton, A Fichtenholtz, GA Otto, K Wang, SR Downing, J He, ... Nature biotechnology 31 (11), 1023-1031, 2013 | 2162 | 2013 |
| Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors GM Frampton, SM Ali, M Rosenzweig, J Chmielecki, X Lu, TM Bauer, ... Cancer discovery 5 (8), 850-859, 2015 | 733 | 2015 |
| Methotrexate‐immobilized poly (ethylene glycol) magnetic nanoparticles for MR imaging and drug delivery N Kohler, C Sun, A Fichtenholtz, J Gunn, C Fang, M Zhang Small 2 (6), 785-792, 2006 | 522 | 2006 |
| Integrated genomic DNA/RNA profiling of hematologic malignancies in the clinical setting J He, O Abdel-Wahab, MK Nahas, K Wang, RK Rampal, AM Intlekofer, ... Blood, The Journal of the American Society of Hematology 127 (24), 3004-3014, 2016 | 280 | 2016 |
| Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors. Cancer Discov. 2015; 5: 850–859 … GM Frampton, SM Ali, M Rosenzweig, J Chmielecki, X Lu, TM Bauer, ... Go to original source... Go to PubMed, 2015 | 115 | 2015 |
| Noninstrumented nucleic acid amplification assay BH Weigl, G Domingo, J Gerlach, D Tang, D Harvey, N Talwar, ... Microfluidics, BioMEMS, and Medical Microsystems VI 6886, 42-53, 2008 | 9 | 2008 |
| Identification of actionable genomic alterations in hematologic malignancies by a clinical next generation sequencing-based assay D Lipson, MK Nahas, GA Otto, R Yelensky, O Abdel-Wahab, K Wang, ... Blood, The Journal of the American Society of Hematology 122 (21), 230-230, 2013 | 5 | 2013 |
| Development and analytical validation of a clinical next generation sequencing-based assay for hematolymphoid malignancies J He, D Lipson, M Nahas, GA Otto, K Wang, KM Knapp, KW Brennan, ... Proceedings of the American Association for Cancer Research Annual Meeting, 5-9, 2014 | 4 | 2014 |
| Activation of MET via diverse exon 14 skipping mutations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors GM Frampton, S Ali, J Chmielecki, M Rosenzweig, T Brennan, Z Chalmers, ... Cancer Research 75 (15_Supplement), 1118-1118, 2015 | 1 | 2015 |
| Bringing next generation sequencing (NGS) to the clinic: Analytical validation of a comprehensive NGS-based cancer gene test. R Yelensky, GM Frampton, A Fichtenholtz, S Downing, J He, F Juhn, ... Cancer Research 73 (8_Supplement), 2279-2279, 2013 | 1 | 2013 |
| Chemically-heated non-instrumented nucleic-acid amplification assay platform B Weigl, GJ Domingo, J Gerlach, J Wilmoth, D Tang, D Harvey, N Talwar, ... 40th Annual American Association of Clinical Chemistry Oak Ridge Conference, 2008 | 1 | 2008 |
| COMPREHENSIVE GENOMIC ANALYSIS OF YOUNG ADULT GLIOBLASTOMAS REVEALS FOUR SUBCLASSES WITH DISTINCT DRIVER EVENTS S Ramkissoon, M Chang, A Johnson, L Gay, J Chmielecki, J Elvin, J Suh, ... NEURO-ONCOLOGY 18, 113-114, 2016 | | 2016 |
| Unsupervised latent class analysis of adult glioma variant profiles reveals biologically and clinically relevant subclasses M Chang, S Ramkissoon, H Bokhari, A Fichtenholtz, S Ali, JS Ross, ... Annals of Oncology 27, vi545, 2016 | | 2016 |
| Abstract LB-328: Subtypes of urothelial carcinoma of the urinary bladder defined by genomic alteration combinations predict clinical characteristics A Khan, A Fichtenholtz, J Ross, G Frampton, E Neumann, SM Ali, ... Cancer Research 76 (14_Supplement), LB-328-LB-328, 2016 | | 2016 |
| Subtypes of urothelial carcinoma of the urinary bladder defined by genomic alteration combinations predict clinical characteristics A Khan, A Fichtenholtz, J Ross, G Frampton, E Neumann, SM Ali, ... CANCER RESEARCH 76, 2016 | | 2016 |
| Latent class analysis of bladder urothelial carcinoma to reveal sub-classes defined by alterations to chromatin and signal transduction networks. A Fichtenholtz, A Khan, JS Ross, SM Ali, VA Miller, PJ Stephens, ... Journal of Clinical Oncology 34 (2_suppl), 469-469, 2016 | | 2016 |
| PREDICTING SIGNIFICANCE OF UNKNOWN VARIANTS IN GLIAL TUMORS THROUGH SUB-CLASS ENRICHMENT AM Fichtenholtz, ND Camarda, EK Neumann Biocomputing 2016: Proceedings of the Pacific Symposium, 297-308, 2016 | | 2016 |
| The complex genomic landscape of glial tumors reveals distinct subclasses and potential therapeutic targets associated with clinical responses to targeted inhibitors J Chmielecki, ME Goldberg, A Fichtenholtz, J Elvin, GM Frampton, SM Ali, ... Cancer Research 75 (15_Supplement), 4667-4667, 2015 | | 2015 |
| Comprehensive Genomic Profiling of Brain Glioblastoma Reveals Frequent Clinically Relevant Genomic Alterations Z Chalmers, S Ali, J Elvin, D Lipson, K Wang, R Yelensky, J Chmielecki, ... LABORATORY INVESTIGATION 95, 429A-429A, 2015 | | 2015 |
| Development and validation of a clinical next generation sequencing-based assay for hematologic malignancies D Lipson, MK Nahas, GA Otto, J He, K Wang, KM Knapp, KW Brennan, ... Cancer Research 74 (19_Supplement), 3570-3570, 2014 | | 2014 |
Conroy SunAssociate Professor, Oregon State University, College of PharmacyVerified email at oregonstate.edu
